Form 4: Director Laura Hamill Granted Stock Options at Fate Therapeutics

Fate Therapeutics reports a stock option grant to Director Laura Hamill, with vesting over three years.

Summary

• Director Laura Hamill was granted stock options for 175,800 shares of common stock.
• The options have an exercise price of $2.06 per share.
• The grant was made on June 12, 2026, and is subject to the company's Non-Employee Director Compensation Policy.
• Vesting will occur in 36 equal monthly installments starting from June 12, 2026, with full vesting expected by June 12, 2029, contingent on continued service.
• This transaction is filed under SEC Form 4, indicating a change in beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Director Hamill received a significant stock option grant, aligning her interests with the company's performance.
• The vesting schedule over three years encourages long-term commitment and service.
• The grant is part of a standard compensation policy for non-employee directors.

Risks

• The value of the stock options is dependent on the future performance of Fate Therapeutics' stock price.
• Continued service is required for vesting, meaning any departure before full vesting results in forfeiture of unvested options.

Future Outlook

The future outlook for the stock options is tied to the company's performance and the director's continued service, with full vesting expected by June 12, 2029.

Industry Context

StockSavvy.ai notes that grants of stock options to directors are a common practice in the biotechnology and pharmaceutical sectors to incentivize leadership and align executive interests with shareholder value, especially during periods of development and potential growth.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns director interests with shareholder value, potentially leading to decisions that benefit the company's stock price.
• Employees: The compensation structure for directors is a component of overall corporate governance.
• Management: The grant is part of the established compensation framework for the board.

Next Steps

• Director Hamill will continue to serve the Issuer.
• The stock options will vest monthly over 36 installments until June 12, 2029.

Key Dates

Keywords

stock options, director compensation, beneficial ownership, Form 4, Fate Therapeutics, equity grant, vesting schedule